Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-0893. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR known ✓ | P47871 | 20/20 | 1.00 |
| ▸ | GIPR | P48546 | 13/20 | 1.00 |
| ▸ | VIPR2 | P41587 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | VIPR1 | P32241 | 1/20 | 1.00 |
| ▸ | DUSP2 | Q05923 | 1/20 | 1.00 |
| ▸ | GLP1R | P43220 | 2/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0893 SCHEMBL2355321 | 1.00 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| Mk-0893 SCHEMBL675777 | 1.00 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL13644751 | 0.94 | GCGR (0.88) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2667874 | 0.92 | GCGR (0.84) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2667510 | 0.92 | GCGR (0.84) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2667512 | 0.91 | GCGR (0.83) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL3251729 | 0.91 | GCGR (0.83) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL825813 | 0.91 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL1966239 | 0.91 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL827984 | 0.91 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114504573-A | Application of MK-0893 in preparing products for inhibiting coronavirus and medicines for resisting coronavirus infection | 山东大学 | 2022-05-17 | — | — | CN | claimed |
| US-12624116-B2 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling | REGENERON PHARMACEUTICALS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735449-A1 | TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE | OmniAB, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4705296-A1 | HETEROARYLINDOLE INHIBITORS OF APOL-1 | OmniAB, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4225739-B1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-3954436-B1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | ORIZURU THERAPEUTICS INC (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-11319376-B2 | Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer | REMD BIOTHERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220112182-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220112181-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3974413-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-106573966-B | Compositions and methods for treating metabolic abnormalities | NGM生物制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3954436-A1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | Orizuru Therapeutics, Inc. (JP) | 2022-02-16 | — | — | EP | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-113993528-A | Method for producing living body-like tissue structure | 千纸鹤治疗公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624116-B2 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling | GCGR, INSR, INSRR | GCGR 1/4885GIPR 6/4885VIPR2 78/4885 |
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | GCGR 128/4885GIPR 501/4885VIPR2 3703/4885 |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | GCGR 190/4885GIPR 181/4885VIPR2 2037/4885 |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | FLT1, KDR, FLT4 | GCGR 407/4885GIPR 237/4885VIPR2 1355/4885 |
| US-20220112182-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | GCGR 210/4885GIPR 665/4885VIPR2 3170/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | GCGR 112/4885GIPR 100/4885VIPR2 2960/4885 |
| US-20220112181-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, MOGAT2 | GCGR 338/4885GIPR 675/4885VIPR2 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.